about
Opioid therapy pharmacogenomics for noncancer pain: efficacy, adverse events, and costsHow drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionPharmacogenetics and pharmacogenomicsSafety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeineMolecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugsWhat is the impact of the ACE gene insertion/deletion (I/D) polymorphism on the clinical effectiveness and adverse events of ACE inhibitors?--Protocol of a systematic reviewPredicting risk of adverse drug reactions in older adultsWithin and beyond the communal turn to informed consent in industry-sponsored pharmacogenetics research: merits and challenges of community advisory boardsThe potential utility of pharmacogenetic testing in psychiatryThe c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patientsA systematically combined genotype and functional combination analysis of CYP2E1, CYP2D6, CYP2C9, CYP2C19 in different geographic areas of mainland China--a basis for personalized therapyPredictors of Prolonged TB Treatment in a Dutch Outpatient SettingProgress and prospects in pharmacogenetics of antidepressant drugs.Of drug administration, war and oïkos: mediating cancer with nanomedicines.Genome-wide gene-environment interactions on quantitative traits using family data.The use of toxicogenomic data in risk assessment: a regulatory perspective.Data-driven methods to discover molecular determinants of serious adverse drug events.Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Large-scale single-nucleotide polymorphism (SNP) and haplotype analyses, using dense SNP Maps, of 199 drug-related genes in 752 subjects: the analysis of the association between uncommon SNPs within haplotype blocks and the haplotypes constructed wiComputational methods for early predictive safety assessment from biological and chemical data.Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.Ethical and legal implications of pharmacogenomics.Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy.SNP genotyping on a genome-wide amplified DOP-PCR template2001: Things to come.Acetylation pharmacogenetics and renal function in diabetes mellitus patients.Role of CYP2E1 immunoglobulin G4 subclass antibodies and complement in pathogenesis of idiosyncratic drug-induced hepatitis.Genetic strategies for the personalization of antipsychotic treatment.Pharmacogenetics: the ethical context.In silico approaches to mechanistic and predictive toxicology: an introduction to bioinformatics for toxicologists.Genetic research with stored biological materials: ethics and practice.Cerivastatin, genetic variants, and the risk of rhabdomyolysis.Novel DNA sequence variations of cytochrome P450 genes in the Han Chinese population.Copy number variants in pharmacogenetic genes.Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer.The use of anti-tuberculosis therapy for latent TB infectionPharmacogenetics in drug regulation: promise, potential and pitfalls.Modulation of the pentose phosphate pathway alters phase I metabolism of testosterone and dextromethorphan in HepG2 cells.Pharmacogenomics: marshalling the human genome to individualise drug therapy
P2860
Q21284753-78C4C541-545C-4417-A202-F772AEA8FFD7Q24273350-6154157F-649B-4E26-8C4E-D897F32CC2E7Q24564983-D49BFDD8-9521-47FB-9D33-242A48DD7255Q24675270-71EC3D70-46CC-4C69-B14A-196FC9DF1DF9Q24683013-2203BCE4-CBEB-4BB5-AE4C-C011D1EEB6D5Q24794522-63C7AAE5-D92B-4D1E-B820-19FC2336D860Q26770379-2242F865-F137-468F-92E9-93A4514EED1AQ28079485-B89B4B59-D8A3-4AEA-B4DB-5DFFEFCEBF38Q28084874-F61E007D-FE68-4F9F-9E28-075366D4AB51Q28306899-F2006B67-5724-49BD-9CFE-FC6030383B29Q28533992-8D7CD434-0BC2-407D-848A-5390FC4BDEE4Q28553471-97CBA026-DAA5-45E4-A609-0C1A9CF00E28Q30249569-CE19114B-AB1B-49FC-91B4-68C7C7F7B75CQ30380301-DE34FF7C-E29B-4C75-BBCB-19703C8BA497Q30488613-C20A8272-019E-43A2-BE2C-4BE50A6D4C5FQ30986903-9CFF17CF-EF18-4AA9-A9D4-8918BEC902DFQ33403734-651FAFE6-11F7-4E14-97F5-8ABABDD5C38CQ33410375-808EF492-0630-47DB-8840-2396511EB3EAQ33998500-FCEB82FF-6305-471A-819C-E0E8A1AC2649Q34066066-A4E650A2-263F-485D-8A3D-CDE03D8C1060Q34131354-CCB7597D-8A48-4B5C-9582-54D94A4CC622Q34188160-0F250090-1773-478D-B9B9-DE9D76C7FFE0Q34327769-2FF0C139-3804-45A7-8B93-6D66E64BCD63Q34368342-BC19D5C2-C7FC-4E09-B70E-9BAE748C9F93Q34369604-1A423A79-782D-4BE6-B066-EA9E0D643453Q34374347-F316D783-7820-4D1A-BB5D-1182784735B7Q34405802-2137407B-D8F5-4977-9208-631F6D66B8B0Q34429256-8F26CE83-B18A-4B3B-BF50-0704A3D0A041Q34569287-0052304F-7C6D-4496-95C2-5230BB30EF1BQ34574028-AB9F47AD-3478-40A4-88C0-A7DB2EF51E2FQ34599613-79BAF56E-1EDC-446A-ABFD-EF539E1BD1D8Q34643365-426976EE-F764-44E8-B11A-4A2F4BA0DD2EQ34792178-C7A8F8AB-409B-4999-8795-53763867FD26Q34963630-08D6E657-0FFC-4200-A3CC-771A87577388Q34975631-C6EE2748-8AC6-4284-B846-664594746819Q35000906-9656B4CA-84F4-4A78-A065-3E8EF3916701Q35026573-C635AB2F-E8DB-4DBC-B01D-7795D542A0E0Q35038052-D92EF003-872B-491E-BD26-944CAE802FA6Q35080177-CFBB7005-053B-499C-9FD0-DF92BDEB8D33Q35090217-1F7D608D-F7C5-40FF-85CA-9A14149EF6DC
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Pharmacogenetics and adverse drug reactions.
@ast
Pharmacogenetics and adverse drug reactions.
@en
Pharmacogenetics and adverse drug reactions.
@nl
type
label
Pharmacogenetics and adverse drug reactions.
@ast
Pharmacogenetics and adverse drug reactions.
@en
Pharmacogenetics and adverse drug reactions.
@nl
prefLabel
Pharmacogenetics and adverse drug reactions.
@ast
Pharmacogenetics and adverse drug reactions.
@en
Pharmacogenetics and adverse drug reactions.
@nl
P1433
P1476
Pharmacogenetics and adverse drug reactions.
@en
P2093
P304
P356
10.1016/S0140-6736(00)03167-6
P407
P577
2000-11-01T00:00:00Z